Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Plasminogen Activators, Tissue Degradation, and Cancer

1985 • 2,584 citations

Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor

1991 • 509 citations

Plasminogen activator inhibitors: hormonally regulated serpins

1990 • 409 citations

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

1987 • 307 citations

Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

1994 • 296 citations

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1988 • 294 citations

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

1992 • 239 citations

Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer

1991 • 236 citations

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

1994 • 230 citations

Plasminogen Activation by Receptor-Bound Urokinase

1991 • 214 citations

Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

1994 • 205 citations

Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer

1990 • 189 citations

Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma

1994 • 169 citations

Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

1994 • 167 citations

Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture

1976 • 161 citations

Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer

1995 • 161 citations

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas

1994 • 159 citations

Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based Chemotherapy

1994 • 140 citations

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

1993 • 122 citations

Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

1995 • 106 citations

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

1995 • 96 citations

The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

1995 • 79 citations

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1994 • 63 citations

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours

1991 • 59 citations

The plasminogen‐activation system in ovarian tumors

1993 • 53 citations